Eric Hu, Ph.D.

Eric Hu, Ph.D., serves as Chief Business Officer at Expedition Therapeutics, where he leads corporate strategy, business development, and partnerships, and supports fundraising and commercial initiatives. Prior to joining Expedition, Dr. Hu was Vice President of Corporate Development and Strategy and Head of U.S. Operations at Overland Pharmaceuticals, where he helped establish Overland Therapeutics and advance the company’s CAR-T programs. Before that, he was a senior member of the business development team at Turning Point Therapeutics prior to its $4.1 billion acquisition by Bristol Myers Squibb. Earlier in his career, Dr. Hu conducted research in antivirals, inflammation, and oncology before serving as an oncology search and evaluation liaison at Gilead Sciences. He earned his Ph.D. in Organic Chemistry from UCLA and his B.S. in Chemistry from Beijing Normal University.